Search

Displaying results 6791 - 6800 of 7059 in total
  1. Drug

    Terevalefim

    go.drugbank.com/drugs/DB16397
    Investigational

    Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).

  2. Drug

    Vafidemstat

    go.drugbank.com/drugs/DB16446
    Investigational

    Vafidemstat is under investigation in clinical trial NCT03867253 (Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease).

  3. Drug

    Tin protoporphyrin IX

    go.drugbank.com/drugs/DB16449
    Investigational

  4. Drug

    Efzofitimod

    go.drugbank.com/drugs/DB16453
    Investigational

    Efzofitimod (ATYR1923) is a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody. … It is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states.

  5. Drug

    XPro1595

    go.drugbank.com/drugs/DB16454
    Investigational

    XPro1595 is an investigational dominant-negative protein that neutralizes soluble TNF.

    Synonyms: HOMOSAPIENS TUMOR NECROSIS FACTOR,SOLUBLE FORM (V1>M, R31>C, C69>V, Y87>H, C101>A, A145>R), MONOMER, PEGYLATED ON CYSTEINE 31 : S-((3RS)-(2-((3-(.OMEGA.
  6. Drug

    Human Interleukin 8

    go.drugbank.com/drugs/DB16456
    Investigational

    Interleukin-8 is under investigation in clinical trial NCT05148234 (BMS-986253 in Myelodysplastic Syndromes).

  7. Drug

    Ezurpimtrostat

    go.drugbank.com/drugs/DB16458
    Investigational

  8. Drug

    TD-0903

    go.drugbank.com/drugs/DB16463
    Investigational

    TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants

  9. Drug

    CIGB 300

    go.drugbank.com/drugs/DB16464
    Investigational

    CIGB-300, is under investigation in clinical trials for its potential to treat various conditions, including NCT01639638 (recurrent and nonrecurrent condyloma) and NCT01639625 (squamous cell carcinoma and adenocarcinoma of the cervix)

  10. Drug

    Meplazumab

    go.drugbank.com/drugs/DB16465
    Investigational

    Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.